Abstract
Hypertension provoked since the beginning of the 19th century a medical debate between physicians. The early antihypertensive agents were poorly tolerated. Progress towards more effective drugs, appeared after the 2nd World War. Thiocyanates, dehydrogenated alkaloids of ergot, barbiturates, bismuth and bromides, were soon replaced by phenoxbenzamine, hexamethonium, pentolinium, and mecamylamine. Thiazide diuretics were the biggest breakthrough during the early 1960's. Then Beta(β)-blockers and angiotensinconverting enzyme inhibitors heralded a new era, until 1995, when losartan, the first non-peptide anti-hypertensive drug, was introduced. The plethora of the antihypertensive drugs changed the relationship between physicians and patients, pushed medicine towards prevention, and altered the medical marketing forever.
Keywords: Antihypertensive drugs, thiazide diuretics, Beta(β)-blockers, angiotensin-converting enzyme inhibitors, losartan, physicianpatient relationship, medical marketing.
Current Pharmaceutical Design
Title:Milestones in Antihypertensive Drug Treatment
Volume: 21 Issue: 6
Author(s): Gregory Tsoucalas, Marianna Karamanou, Manolis Vavuranakis, Markos Sgantzos, Christodoulos Stefanadis and Georgios Androutsos
Affiliation:
Keywords: Antihypertensive drugs, thiazide diuretics, Beta(β)-blockers, angiotensin-converting enzyme inhibitors, losartan, physicianpatient relationship, medical marketing.
Abstract: Hypertension provoked since the beginning of the 19th century a medical debate between physicians. The early antihypertensive agents were poorly tolerated. Progress towards more effective drugs, appeared after the 2nd World War. Thiocyanates, dehydrogenated alkaloids of ergot, barbiturates, bismuth and bromides, were soon replaced by phenoxbenzamine, hexamethonium, pentolinium, and mecamylamine. Thiazide diuretics were the biggest breakthrough during the early 1960's. Then Beta(β)-blockers and angiotensinconverting enzyme inhibitors heralded a new era, until 1995, when losartan, the first non-peptide anti-hypertensive drug, was introduced. The plethora of the antihypertensive drugs changed the relationship between physicians and patients, pushed medicine towards prevention, and altered the medical marketing forever.
Export Options
About this article
Cite this article as:
Tsoucalas Gregory, Karamanou Marianna, Vavuranakis Manolis, Sgantzos Markos, Stefanadis Christodoulos and Androutsos Georgios, Milestones in Antihypertensive Drug Treatment, Current Pharmaceutical Design 2015; 21 (6) . https://dx.doi.org/10.2174/1381612820666141023163552
DOI https://dx.doi.org/10.2174/1381612820666141023163552 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Overuse of PPIs in Patients at Admission, During Hospitalisation, and at Discharge in a Terciary Spanish Hospital
Current Clinical Pharmacology A Simplified Protocol for Routine Chemoselective Syntheses of Piperazines Substituted in the 1-Position by an Electron Withdrawing Group
Current Organic Synthesis Regulation of Inflammatory Responses by Sensory Neurons: Molecular Mechanism(s) and Possible Therapeutic Applications
Current Medicinal Chemistry Sphingolipids in Genetic and Acquired Forms of Chronic Kidney Diseases
Current Medicinal Chemistry Classical and Innovative Insulin Sensitizing Drugs for the Prevention and Treatment of NAFLD
Current Pharmaceutical Design Microwave-Assisted Synthesis of N-Alkylated Bibenzoimidazolyl Derivatives: Antimicrobial Studies
Letters in Drug Design & Discovery Masked Hypertension and Diabetes
Current Hypertension Reviews Adipose Tissue as a Regulator of Energy Balance
Current Drug Targets Job Stress and Blood Pressure: A Critical Appraisal of Reported Studies
Current Hypertension Reviews Factors Influencing the Hemodynamic and Metabolic Effects of Insulin in Muscle
Current Diabetes Reviews Myocardial Expression of TNF-α, IL-1β, IL-6, IL-8, IL-10 and MCP-1 After a Single MDMA Dose Administered in a Rat Model
Current Pharmaceutical Biotechnology Uric Acid in Metabolic and Cerebrovascular Disorders: A Review
Current Vascular Pharmacology Eisenmenger Syndrome: Recent Advances in Pharmacotherapy
Cardiovascular & Hematological Agents in Medicinal Chemistry Mechanisms of Esophageal Protection, Gastroprotection and Ulcer Healing by Melatonin. Implications for the Therapeutic use of Melatonin in Gastroesophageal Reflux Disease (GERD) and Peptic Ulcer Disease
Current Pharmaceutical Design Pharmacogenetically Tailored Treatments for Heart Disease
Current Pharmaceutical Design Anti-Platelet Treatment of Middle-Sized Abdominal Aortic Aneurysms
Current Vascular Pharmacology Prediction of Biological Activity Spectra for Substances: Evaluation on the Diverse Sets of Drug-Like Structures
Current Medicinal Chemistry Pathophysiology of Platelet Resistance to Anti-Aggregating Agents in Insulin Resistance and Type 2 Diabetes: Implications for Anti-Aggregating Therapy
Cardiovascular & Hematological Agents in Medicinal Chemistry Sleep Loss and Hypertension: A Systematic Review
Current Pharmaceutical Design Measurement of Physical Changes in the Myocardium for Development of Novel Methods for Diagnosing Ischemia
Current Cardiology Reviews